Eli Lilly (LLY), the pharmaceutical company behind Zepbound and Mounjaro, gained 6% after strong third quarter results. Adjusted EPS reached $7.48, ahead of $6.26 expected. Revenue increased to $24.4bn, exceeding expectations of $22.61bn.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
